AR
PCRX icon

Advisory Research’s Pacira BioSciences PCRX Stock Holding History

Advisory Research’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-25,625
Closed -$1.1M – 370
2018
Q4 		$1.1M Buy
+25,625
New +$1.2M 0.02% 230

Other funds holding PCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Advisory Research's PCRX Position: Q1 2019 in Review

Advisory Research sold out of Pacira BioSciences (PCRX) in Q1 2019, closing a stake of 25,625 shares — an estimated $1.1M sold.

Advisory Research first reported a position in PCRX in Q4 2018 and held it in 1 quarter. The position peaked at $1.1M in Q4 2018. 210 funds tracked by Wall St. Rank hold PCRX as of Q1 2019.

  • Advisory Research reported no remaining Pacira BioSciences position as of Q1 2019 after selling out during the quarter.
  • Advisory Research sold 25,625 Pacira BioSciences shares in Q1 2019, an estimated $1.1M.
  • Advisory Research first reported a position in Pacira BioSciences in Q4 2018 and held it in 1 quarter.
  • Advisory Research's Pacira BioSciences position peaked at $1.1M in Q4 2018.
  • 210 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2019.

Based on Advisory Research's 13F filing for Q1 2019, filed 15 May 2019.